JP2001523264A5 - - Google Patents

Download PDF

Info

Publication number
JP2001523264A5
JP2001523264A5 JP1998548048A JP54804898A JP2001523264A5 JP 2001523264 A5 JP2001523264 A5 JP 2001523264A5 JP 1998548048 A JP1998548048 A JP 1998548048A JP 54804898 A JP54804898 A JP 54804898A JP 2001523264 A5 JP2001523264 A5 JP 2001523264A5
Authority
JP
Japan
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP1998548048A
Other languages
English (en)
Other versions
JP5033276B2 (ja
JP2001523264A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US1998/003197 external-priority patent/WO1998050060A1/en
Publication of JP2001523264A publication Critical patent/JP2001523264A/ja
Publication of JP2001523264A5 publication Critical patent/JP2001523264A5/ja
Application granted granted Critical
Publication of JP5033276B2 publication Critical patent/JP5033276B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Description

Figure 2001523264
Figure 2001523264
Figure 2001523264
Figure 2001523264
Figure 2001523264
JP54804898A 1997-05-05 1998-05-05 急性腎不全の治療 Expired - Fee Related JP5033276B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US4561997P 1997-05-05 1997-05-05
US60/045,619 1997-05-05
PCT/US1998/003197 WO1998050060A1 (en) 1997-05-05 1998-05-05 Therapies for acute renal failure

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2009211128A Division JP2009286802A (ja) 1997-05-05 2009-09-11 急性腎不全の治療

Publications (3)

Publication Number Publication Date
JP2001523264A JP2001523264A (ja) 2001-11-20
JP2001523264A5 true JP2001523264A5 (ja) 2005-12-02
JP5033276B2 JP5033276B2 (ja) 2012-09-26

Family

ID=21938961

Family Applications (2)

Application Number Title Priority Date Filing Date
JP54804898A Expired - Fee Related JP5033276B2 (ja) 1997-05-05 1998-05-05 急性腎不全の治療
JP2009211128A Withdrawn JP2009286802A (ja) 1997-05-05 2009-09-11 急性腎不全の治療

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2009211128A Withdrawn JP2009286802A (ja) 1997-05-05 2009-09-11 急性腎不全の治療

Country Status (11)

Country Link
US (2) US20100105621A1 (ja)
EP (1) EP0980252B1 (ja)
JP (2) JP5033276B2 (ja)
AT (1) ATE278414T1 (ja)
AU (1) AU743510B2 (ja)
CA (1) CA2289123A1 (ja)
DE (1) DE69826854T2 (ja)
DK (1) DK0980252T3 (ja)
ES (1) ES2226125T3 (ja)
PT (1) PT980252E (ja)
WO (1) WO1998050060A1 (ja)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7612046B2 (en) 2000-01-31 2009-11-03 Uwe Waldemar Rothenpieler Method for treating kidney disorders
DE60143078D1 (de) * 2000-01-31 2010-10-28 Uwe Waldemar Rothenpieler Pax2 zur behandlung von nierenkrankheiten
EP1407770B1 (en) * 2001-06-26 2013-06-05 Takeda Pharmaceutical Company Limited Tgf-beta superfamily production/secretion promoter
JP2006516020A (ja) * 2002-08-28 2006-06-15 キュリス インコーポレイテッド 慢性腎不全の治療におけるモルフォゲン及びａｃｅ阻害薬の共投与
CA2629522A1 (en) * 2005-11-14 2007-05-18 Merial Limited Gene therapy for renal failure
EP2047862B9 (en) * 2006-07-21 2013-04-10 Chugai Seiyaku Kabushiki Kaisha Remedy for renal disease
US8979797B2 (en) * 2010-12-16 2015-03-17 Ams Research Corporation High pressure delivery system and method for treating pelvic disorder using large molecule therapeutics
US8956829B2 (en) 2013-01-25 2015-02-17 Warsaw Orthopedic, Inc. Human recombinant growth and differentiaton factor-5 (rhGDF-5)
US8945872B2 (en) 2013-01-25 2015-02-03 Warsaw Orthopedic, Inc. Methods of purifying human recombinant growth and differentiation factor-5 (rhGDF-5) protein
US9359417B2 (en) 2013-01-25 2016-06-07 Warsaw Orthopedic, Inc. Cell cultures and methods of human recombinant growth and differentiaton factor-5 (rhGDF-5)
US9051389B2 (en) 2013-01-25 2015-06-09 Warsaw Orthopedic, Inc. Expression conditions and methods of human recombinant growth and differentiation factor-5 (rhGDF-5)
US9169308B2 (en) 2013-01-25 2015-10-27 Warsaw Orthopedic, Inc. Methods and compositions of human recombinant growth and differentiation factor-5 (rhGDF-5) isolated from inclusion bodies
SG11201606514SA (en) 2014-02-07 2016-09-29 Toru Miyazaki Preventive or therapeutic agent for kidney disease
FR3071065B1 (fr) 2017-09-08 2020-10-02 Dcns Dispositif de controle d'isolement et/ou de continuite d'au moins un cable electrique et procede de controle associe

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1156741B (it) 1978-05-15 1987-02-04 Sigma Tau Ind Farmaceuti Applicazione terapeutica della carnitina e di alcuni derivati acilati della carnitina nell'emodialisi
US4342828A (en) 1979-07-20 1982-08-03 Morinaga Milk Industry Co., Ltd. Method for producing substance capable of stimulating differentiation and proliferation of human granulopoietic stem cells
US4627839A (en) * 1985-11-21 1986-12-09 American Hospital Supply Corporation Patient controlled analgesia conversion
IL83003A (en) 1986-07-01 1995-07-31 Genetics Inst Factors that soak bone formation
US5013649A (en) * 1986-07-01 1991-05-07 Genetics Institute, Inc. DNA sequences encoding osteoinductive products
US5266683A (en) * 1988-04-08 1993-11-30 Stryker Corporation Osteogenic proteins
US5011691A (en) * 1988-08-15 1991-04-30 Stryker Corporation Osteogenic devices
US5045452A (en) * 1988-09-02 1991-09-03 Brigham And Women's Hospital Method for evaluating nephrotoxicity
CA2030518C (en) 1989-03-28 2000-03-21 Elizabeth A. Wang Osteoinductive compositions
DE69132823T2 (de) 1990-05-16 2002-07-18 Genetics Inst Knochen- und knorpel-bildung hervorrufende proteine
JPH0426624A (ja) 1990-05-18 1992-01-29 Tsumura & Co 慢性腎不全改善剤
ATE146076T1 (de) 1990-06-22 1996-12-15 Du Pont Behandlung des chronischen nierenversagens mit imidazol-angiotensin-ii-rezeptorantagonisten
US6077823A (en) * 1991-03-11 2000-06-20 Creative Biomolecules, Inc. Method for reducing tissue damage associated with ischemia-reperfusion or hypoxia injury
AU660019B2 (en) 1991-03-11 1995-06-08 Stryker Corporation Protein-induced morphogenesis
US6194376B1 (en) * 1991-03-11 2001-02-27 Creative Biomolecules, Inc. Method for modulating inflammatory response comprising administering morphogen
CA2104678C (en) * 1991-03-11 2002-05-14 Charles M. Cohen Protein-induced morphogenesis
US7056882B2 (en) * 1991-03-11 2006-06-06 Curis, Inc. Treatment to prevent loss of and/or increase bone mass in metabolic bone diseases
US5849686A (en) * 1991-03-11 1998-12-15 Creative Biomolecules, Inc. Morphogen-induced liver regeneration
US6287816B1 (en) 1991-06-25 2001-09-11 Genetics Institute, Inc. BMP-9 compositions
EP0601129B1 (en) 1991-08-30 2000-11-15 Creative Biomolecules, Inc. Morphogenic protein screening method
EP1637156A1 (en) * 1991-08-30 2006-03-22 Curis, Inc. Systemic administration of osteogenic proteins in the treatment of metabolic bone diseases
AU669127B2 (en) * 1991-08-30 1996-05-30 Stryker Corporation Morphogen-induced modulation of inflammatory response
US6120760A (en) * 1992-02-12 2000-09-19 Biopharm Gesellschaft Zur Biotechnologischen Entwicklung Growth/differentiation factors of the TGF-β family
DE69318166T2 (de) 1992-07-31 1998-10-08 Creative Biomolecules Inc Mit morphogen angereicherte nahrungszusammenstellung
ATE287949T1 (de) 1992-07-31 2005-02-15 Stryker Corp Löslicher komplex morphogener proteine und zusammensetzungen davon
ATE242639T1 (de) * 1992-07-31 2003-06-15 Curis Inc Morphogen induzierte nerven wiederherstellung und wiedergutmachung.
CA2144514C (en) 1992-09-16 2002-03-26 Thangavel Kuberasampath Morphogen-induced liver regeneration
AU681362B2 (en) 1992-11-03 1997-08-28 Stryker Corporation OP-3-induced morphogenesis
DE69434914T2 (de) 1993-03-04 2007-10-31 Stryker Corp., Kalamazoo Verfahren und zusammensetzungen zur herstellung von rekombinantem osteogenischem protein
US5631159A (en) 1993-09-22 1997-05-20 Creative Biomolecules, Inc. Lipid-modified serum free media
US5585237A (en) 1993-10-25 1996-12-17 Creative Biomolecules, Inc. Methods and compositions for high protein production from recombinant DNA
AU690941B2 (en) * 1993-11-15 1998-05-07 Celtrix Pharmaceuticals, Inc. Method of treating renal disease by administering IGF-I and IGFBP-3
US5525621A (en) * 1994-05-20 1996-06-11 Cytos Pharmaceuticals Llc Imidazole derivatives as protective agents in reperfusion injury and severe inflammatory responses
US5714511A (en) * 1995-07-31 1998-02-03 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Selective prevention of organ injury in sepsis and shock using selection release of nitric oxide in vulnerable organs
JP2000507939A (ja) * 1996-03-22 2000-06-27 ザ ジェネラル ホスピタル コーポレーション 中枢神経系の虚血または外傷後のポリペプチド成長因子の投与
US5820589A (en) * 1996-04-30 1998-10-13 Medtronic, Inc. Implantable non-invasive rate-adjustable pump
US6498142B1 (en) * 1996-05-06 2002-12-24 Curis, Inc. Morphogen treatment for chronic renal failure
US5879908A (en) * 1997-04-30 1999-03-09 Smithkline Beecham Corporation CRFG-1a, a target and marker for chronic renal failure
US7147839B2 (en) 1998-05-29 2006-12-12 Curis, Inc. Methods for evaluating tissue morphogenesis and activity

Similar Documents

Publication Publication Date Title
JP2000510751A5 (ja)
JP2000509912A5 (ja)
JP2000509637A5 (ja)
JP2000509942A5 (ja)
JP2000507042A5 (ja)
JP2000509635A5 (ja)
JP2000507433A5 (ja)
JP2000509587A5 (ja)
JP2001507846A5 (ja)
JP2000508866A5 (ja)
JP2000510793A5 (ja)
JP2002500588A5 (ja)
JP2000508841A5 (ja)
JP2000509804A5 (ja)
JP2000509853A5 (ja)
JP2001513744A5 (ja)
JP2000509755A5 (ja)
JP2000510969A5 (ja)
JP2000508836A5 (ja)
JP2000509520A5 (ja)
JP2000509818A5 (ja)
JP2000510247A5 (ja)
JP2000507434A5 (ja)
JP2000508880A5 (ja)
JP2001523264A5 (ja)